ArticleCyborg and bionic systems (Washington, D.C.)2026
A Mechanotransduction-Aware Strategy for Enhancing MSC Potency via 3D Culture and Localized Delivery.
Article in Cyborg and bionic systems (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) is characterized by uncontrolled inflammation, oxidative stress, and fibrotic remodeling, yet mesenchymal stem cell (MSC) therapies remain limited by poor retention and insufficient microenvironmental adaptation. Here, we engineered a composite system, GelMA@hMSCs-Alg-RGD (hereafter referred to as the sandwich composite), in which RGD (Arg-Gly-Asp) -functionalized alginate microbeads support human MSCs and are encapsulated within an adhesive, stress-relaxing dopamine-modified GelMA (GelMA-DA) hydrogel. This design provided a 3-dimensional low-tension niche that preserved MSC identity while enhancing paracrine potency, antioxidative capacity, and resistance to apoptosis. Conditioned media from hMSCs-Alg-RGD promoted endothelial proliferation, migration, invasion, and tube formation, while attenuating oxidative stress in a partially cytoskeleton-dependent manner. In fibroblasts, treatment suppressed alpha-smooth muscle actin stress fiber formation, focal adhesion maturation, and Yes-associated protein nuclear translocation, thereby preventing myofibroblast differentiation and restoring isotropic morphology. GelMA@hMSCs-Alg-RGD enabled rapid gelation, robust wet adhesion, stress-relaxing mechanics, and controlled degradation, resulting in prolonged pulmonary retention confirmed by in vivo and ex vivo imaging. In murine ALI, this strategy alleviated edema, reduced inflammatory cytokines (interleukin-6, tumor necrosis factor-α, and interleukin-1β), myeloperoxidase activity, and lipid peroxidation (malondialdehyde), while enhancing superoxide dismutase activity, improving survival, and reshaping the immune microenvironment through reduced neutrophil infiltration and enhanced macrophage M1 → M2 polarization. Together, these results establish GelMA@hMSCs-Alg-RGD as a bioengineered therapeutic that integrates localized retention with paracrine amplification to reprogram immune and mechanical microenvironments, offering a broadly applicable platform for MSC-based regenerative medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.